These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 21877997)

  • 1. Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults.
    Bajaj M; Heath EI
    Expert Opin Biol Ther; 2011 Nov; 11(11):1519-24. PubMed ID: 21877997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.
    Doi T; Murakami H; Ohtsu A; Fuse N; Yoshino T; Yamamoto N; Boku N; Onozawa Y; Hsu CP; Gorski KS; Friberg G; Kawaguchi T; Sasaki T
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):733-41. PubMed ID: 21161528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer.
    Rosevear HM; Lightfoot AJ; Griffith TS
    Curr Opin Investig Drugs; 2010 Jun; 11(6):688-98. PubMed ID: 20496264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies.
    Camidge DR; Herbst RS; Gordon MS; Eckhardt SG; Kurzrock R; Durbin B; Ing J; Tohnya TM; Sager J; Ashkenazi A; Bray G; Mendelson D
    Clin Cancer Res; 2010 Feb; 16(4):1256-63. PubMed ID: 20145186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A first-in-human study of conatumumab in adult patients with advanced solid tumors.
    Herbst RS; Kurzrock R; Hong DS; Valdivieso M; Hsu CP; Goyal L; Juan G; Hwang YC; Wong S; Hill JS; Friberg G; LoRusso PM
    Clin Cancer Res; 2010 Dec; 16(23):5883-91. PubMed ID: 20947515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling.
    Zoog SJ; Ma CY; Kaplan-Lefko PJ; Hawkins JM; Moriguchi J; Zhou L; Pan Y; Hsu CP; Friberg G; Herbst R; Hill J; Juan G
    Cytometry A; 2010 Sep; 77(9):849-60. PubMed ID: 20623688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.
    Demetri GD; Le Cesne A; Chawla SP; Brodowicz T; Maki RG; Bach BA; Smethurst DP; Bray S; Hei YJ; Blay JY
    Eur J Cancer; 2012 Mar; 48(4):547-63. PubMed ID: 22240283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naptumomab estafenatox: a new immunoconjugate.
    Robinson MK; Alpaugh RK; Borghaei H
    Expert Opin Biol Ther; 2010 Feb; 10(2):273-9. PubMed ID: 20053143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types.
    Kaplan-Lefko PJ; Graves JD; Zoog SJ; Pan Y; Wall J; Branstetter DG; Moriguchi J; Coxon A; Huard JN; Xu R; Peach ML; Juan G; Kaufman S; Chen Q; Bianchi A; Kordich JJ; Ma M; Foltz IN; Gliniak BC
    Cancer Biol Ther; 2010 Apr; 9(8):618-31. PubMed ID: 20150762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J; Emons G; Pinski J; Schally AV
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRAIL-receptor antibodies as a potential cancer treatment.
    Buchsbaum DJ; Forero-Torres A; LoBuglio AF
    Future Oncol; 2007 Aug; 3(4):405-9. PubMed ID: 17661715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.
    Sandhu SK; Papadopoulos K; Fong PC; Patnaik A; Messiou C; Olmos D; Wang G; Tromp BJ; Puchalski TA; Balkwill F; Berns B; Seetharam S; de Bono JS; Tolcher AW
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):1041-50. PubMed ID: 23385782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.
    Tolcher AW; Mita M; Meropol NJ; von Mehren M; Patnaik A; Padavic K; Hill M; Mays T; McCoy T; Fox NL; Halpern W; Corey A; Cohen RB
    J Clin Oncol; 2007 Apr; 25(11):1390-5. PubMed ID: 17416859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
    Vonderheide RH; Flaherty KT; Khalil M; Stumacher MS; Bajor DL; Hutnick NA; Sullivan P; Mahany JJ; Gallagher M; Kramer A; Green SJ; O'Dwyer PJ; Running KL; Huhn RD; Antonia SJ
    J Clin Oncol; 2007 Mar; 25(7):876-83. PubMed ID: 17327609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Technology evaluation: mapatumumab, Human Genome Sciences/GlaxoSmithKline/Takeda.
    Vulfovich M; Saba N
    Curr Opin Mol Ther; 2005 Oct; 7(5):502-10. PubMed ID: 16248286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.
    Hotte SJ; Hirte HW; Chen EX; Siu LL; Le LH; Corey A; Iacobucci A; MacLean M; Lo L; Fox NL; Oza AM
    Clin Cancer Res; 2008 Jun; 14(11):3450-5. PubMed ID: 18519776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor.
    Vanhoefer U; Tewes M; Rojo F; Dirsch O; Schleucher N; Rosen O; Tillner J; Kovar A; Braun AH; Trarbach T; Seeber S; Harstrick A; Baselga J
    J Clin Oncol; 2004 Jan; 22(1):175-84. PubMed ID: 14701780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inotuzumab ozogamicin as novel therapy in lymphomas.
    Wong BY; Dang NH
    Expert Opin Biol Ther; 2010 Aug; 10(8):1251-8. PubMed ID: 20528256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors.
    Camidge DR
    Expert Opin Biol Ther; 2008 Aug; 8(8):1167-76. PubMed ID: 18613768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer.
    Keir CH; Vahdat LT
    Expert Opin Biol Ther; 2012 Feb; 12(2):259-63. PubMed ID: 22229970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.